UroMems, a French-American medtech company, has raised $60 million from Ajax Health Fund I – its largest round to date – to fund pivotal clinical trials and commercial launch preparation of UroActive, a smart automated artificial urinary sphincter for stress urinary incontinence (SUI).
SUI – involuntary urinary leakage – affects an estimated 40 million Americans and 90 million Europeans, and disproportionately affects women, particularly after childbirth, during menopause, and as pelvic floor function changes with age. Despite its prevalence, treatment options have remained limited, with existing artificial urinary sphincters requiring manual adjustment and carrying significant complication rates.
UroActive is a smart active implant powered by a MyoElectroMechanical System (MEMS) that is placed around the urethral duct and controlled automatically based on the patient’s activity – no manual adjustments required. The platform is protected by more than 200 granted patents.
The funding will support UroMems through completion of its SOPHIA clinical trial across 21 investigational centers in the U.S. and France, in preparation for regulatory submission to both markets. The investment builds on a $47 million Series C completed in June 2024.
“I believe UroActive will be a game-changer in treating patients suffering from SUI, and we are now one step closer to achieving our shared vision of delivering on the significant unmet need for patients and physicians desperately seeking a better SUI treatment option,” said co-founder and CEO Hamid Lamraoui.
“We believe that the UroActive smart implant has the potential to become the standard of care for SUI treatment,” said David Beylik, partner at Ajax Health, who joins the UroMems board alongside Dr. Jeremy Durack.
